Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899313 | 0.98 | BCHE (0.36) | BCHE | |
| SCHEMBL29899221 | 0.94 | BCHE (0.33) | BCHE | |
| SCHEMBL31234457 | 0.76 | — | — | |
| SCHEMBL21958137 | 0.76 | — | — | |
| SCHEMBL5323068 | 0.76 | AKR1C1 (0.43) | LMNAGAAL3MBTL1 | |
| SCHEMBL19901032 | 0.74 | — | — | |
| SCHEMBL31234410 | 0.73 | — | — | |
| SCHEMBL22576500 | 0.69 | CYP19A1 (0.34) | — | |
| SCHEMBL28461405 | 0.69 | AKR1C1 (0.30) | — | |
| SCHEMBL20259492 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-03 | — | — | US | disclosed |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-08 | — | — | US | disclosed |
| US-10246427-B2 | Derivatives of 1,2,3-triazolyl cyclohexan-1-ol and its use | UNIWERSYTET JAGIELLONSKI (PL) | 2019-04-02 | — | — | US | disclosed |
| US-20180297960-A1 | DERIVATIVES OF 1,2,3-TRIAZOLYL CYCLOHEXAN-1-OL AND ITS USE | UNIWERSYTET JAGIELLONSKI (PL) | 2018-10-18 | — | — | US | disclosed |
| EP-3303319-A1 | DERIVATIVES OF 1,2,3-TRIAZOLYL CYCLOHEXAN-1-OL AND ITS USE | Uniwersytet Jagiellonski (PL) | 2018-04-11 | — | — | EP | disclosed |
| EP-3303319-A1 | DERIVATIVES OF 1,2,3-TRIAZOLYL CYCLOHEXAN-1-OL AND ITS USE | Uniwersytet Jagiellonski (PL) | 2018-04-11 | — | — | EP | disclosed |
| US-20070077641-A1 | Methionine aminopeptidase and methods of use | PALMER LESLIE | 2007-04-05 | — | — | US | disclosed |
| EP-1624849-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005016237-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | BCHE 4321/4885HTR1A 315/4885HTR2A 2190/4885 |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | METAP1, METAP2, DNPEP | BCHE 2503/4885HTR1A 629/4885HTR2A 797/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | BCHE 1234/4885HTR1A 1729/4885HTR2A 635/4885 |
| US-20180297960-A1 | DERIVATIVES OF 1,2,3-TRIAZOLYL CYCLOHEXAN-1-OL AND ITS USE | SOD1, AOC3, AOC2 | BCHE 2735/4885HTR1A 647/4885HTR2A 1059/4885 |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | BCHE 4753/4885HTR1A 384/4885HTR2A 2109/4885 |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | BCHE 4753/4885HTR1A 384/4885HTR2A 2109/4885 |
| US-10246427-B2 | Derivatives of 1,2,3-triazolyl cyclohexan-1-ol and its use | SOD1, AOC3, AOC2 | BCHE 2735/4885HTR1A 647/4885HTR2A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.